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Gonococcal urethritis continues to be a public health problem 
in Malawi. Urethritis accounts for over 20% of  outpatient 
STI clinic visits at Kamuzu Central Hospital in Lilongwe 
annually, and approximately 85% of  urethritis is caused by 
Neisseria gonorrhoeae1-3. Timely and effective treatment 
of  gonococcal urethritis eradicates infection in the affected 
individual, prevents the development of  complications, 
and reduces the duration of  infection, thus preventing 
onward transmission. Gonorrhea is also an important co-
factor for HIV; Neisseria gonorrhoeae infection facilitates 
HIV transmission, while effective treatment of  gonococcal 
urethritis reduces HIV shedding in the genital tract4. 
Additionally, acute HIV is important to HIV transmission5 
and the Acute HIV Programme in Malawi found an 
association between urethritis and likelihood of  acute HIV6. 
Therefore, attention to urethritis is of  great public health 
importance for HIV prevention.
Internationally, several antimicrobial surveillance projects 
exist to monitor the development and spread of  resistance. 
Two major programs are the Gonococcal Antimicrobial 
Susceptibility Program (GASP) monitored by the World 
Health Organization, and the Gonococcal Isolate Surveillance 
Project (GISP) monitored by the US Centers for Disease 
Control and Prevention. These programs use laboratory 
methods to monitor in vitro gonococcal susceptibility and 
provide an objective measure of  resistance.  Clinical cure 
rates, which can be affected by reinfection, are used less 
often for resistance surveillance.
Malawi adopted syndromic management of  sexually 
transmitted infections in 1993.  Based on clinical efficacy 
and cost, gentamicin 240mg IM and doxycycline 100 mg 
BID x 7 days was selected as the first line regimen to treat 
urethritis in the syndromic format7.  Malawi continues to 
stand by its recommended use despite WHO and regional 
recommendations to use ciprofloxacin as first line treatment 
of  uncomplicated gonococcal urethritis.  Local surveillance 
data supports Malawi’s decision.  A recent article in the journal 
Sexually Transmitted Diseases showed 100% susceptibility 
to gentamicin among men treated for urethritis in the 
outpatient sexually transmitted infections and reproductive 
health clinic at Kamuzu Central Hospital in Lilongwe1.  In 
this article agar dilution minimum inhibitory concentration 
(MIC) testing conducted in the United States was used as the 
gold standard in parallel with less technologically challenging 
susceptibility methods of  disc diffusion and e-test conducted 
here in Malawi.  Results obtained from both MIC testing 
and the disc diffusion and E-tests performed locally were 
in agreement for the susceptible isolates.  Trials conducted 
through a collaboration between the MOH and the 
University of  North Carolina that determined clinical cure 
rates and/or laboratory based susceptibility data for men 
with gonoccocal urethritis in Malawi (in both Blantyre and 
Lilongwe) conducted in 1993, 1996, 1998, and 2001-2, and 
most recently in 2007, demonstrate continued susceptibility 
of  gonorrhea to gentamicin at the >95% rate1,3,7.  This 
continued high susceptibility to the first line drug regimen 
stands in contrast to other regions of  the world and 
countries in southern Africa that implemented ciprofloxacin 
as first line treatment.  South Africa saw the proportion of  
gonococcal isolates resistant to ciprofloxacin increase from 
zero to over 40% within 18 months after it was introduced 
as first line treatment for gonococcal urethritis8,9.  This 
dramatic reduction in susceptibility necessitated a switch 
to more costly drugs, such as cephalosporins. Although 
the 2007 GC susceptibility survey shows ciprofloxacin to 
continue to be susceptible in Malawi, it can be expected that 
resistance would rapidly develop if  its use to treat urethritis 
were increased.  
Cost-effective control of  gonococcal urethritis is essential in 
Malawi, particularly given its synergy with HIV.  We believe 
that the Malawi Ministry of  Health made the right choice to 
continue to recommend gentamicin for first line treatment. 
Toxicity related to gentamicin is related to cumulative doses, 
and there are no reported toxicities to a single intramuscular 
injection.  However, this has not been looked at systematically 
and more data are needed on the safety profile of  and proper 
dosing of  gentamicin for treatment of  gonococcal urethritis. 
Additionally, as antimicrobial susceptibilities of  prevailing 
gonococcal strains can change rapidly due to the nature of  the 
bacteria, accurate and periodic assessments of  susceptibility 
patterns are needed.  Sustaining an accredited microbiology 
laboratory is challenging, hence previously the majority of  
the gonococcal susceptibility testing has been performed in 
external labs outside of  Malawi.  It’s encouraging to note 
that the e-test and disc diffusion testing were successfully 
conducted in Malawi and further refinement of  these 
techniques will reduce the dependency on costly testing 
abroad.  While the gold standard for gonococcal microbial 
sensitivity monitoring is Minimum Inhibitory Concentration 
(MIC), our study demonstrated high level of  agreement 
between less technically demanding and less expensive tests 
such as disk diffusion and E-test with the gold standard 
for susceptible isolates. The use of  a turbidometer to 
standardize turbidity of  the culture suspension on the media 
likely improved the correlation between methods compared 
to previous susceptibility surveys2. This is important because 
it shows feasibility of  microbial susceptibility monitoring in 
limited resource setting like Malawi.  Continued surveillance 
is necessary to ensure treatment guidelines are in line with 
current susceptibility trends.  Sustaining the local laboratory 
support will be crucial to these efforts.
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Funding Opportunities from HRCSI
The National Commission for Science and Technology (NCST) is implementing a five-year Health Research Capacity Strengthening 
Initiative (HRCSI). HRCSI is funded by the UK Department for International Development (DFID), Wellcome Trust and International 
Development Research Centre (IDRC). The overall goal of  HRCSI is to build and strengthen health research capacity at both individual 
and organisational levels in Malawi.  At individual level, it provides training and research grant fellowships. At institutional level, HRCSI 
supports the development of  research infrastructure.
HRCSI offers scholarships to Malawians at Masters and PhD levels. Fellowships target particular disciplines.  At Master’s level, the 
following are target disciplines: (a) Biostatistics (b) Demography (c) Health economics (d) Medical anthropology (e) Medical biology (f) 
Medical microbiology (g) Medical pathology (h) Medical chemistry (i) Epidemiology and (j) Health systems: health care financing, human 
resources for health, health information systems, health management and organization, health programme evaluation, procurement and 
supply chain management and health policy. At PhD level, HRCSI scholarships support applicants who intend to specialise in any of  
the following disciplines: (a) Biostatistics (b) Health Economics (c) Medical Microbiology and (d) Medical pathology. HRCSI does not 
process any application from an applicant who intends to specialise in any other field apart from the ones listed above.  
HRCSI makes competitive grants to researchers.  There are three types of  research grants. These are postgraduate dissertation research 
grants, junior and senior research grants. Postgraduate Dissertation Research Grants seek to facilitate more rigorous engagement of  
postgraduate students in research. The maximum values of  Masters and PhD dissertation research grants are $4,000 and $10,000, 
respectively. 
To qualify for postgraduate research grants, applicants must (a) be Malawian citizens (b) be pursuing a Masters or PhD training at a 
recognised university (c) have completed all pre-dissertation requirements e.g. coursework (d) have a research dissertation proposal that 
is on health or health-related topic and (e) provide evidence that the research proposal  has been approved by their supervisors.
Junior research grants support novice researchers who want to develop their career in health research. The value of  each junior research 
grant is a maximum of  US$20,000 per year for up to three years. The applicant for junior research grants must: (a) be a Malawian citizen 
affiliated with a Malawian institution and (b) and have a health-related research topic relevant to Malawi. 
Senior research grant is offered to researchers with a proven track record of  conducting research and managing research grants. The 
value of  senior research grant is a maximum of  US$70,000 per year for up to three years. Applicants must: (a) be Malawian citizens 
affiliated with a Malawian institution (b) have at least three publications in international journals as the first author in the past five years 
(c) have a team of  researchers that includes at least one junior researcher with at least a master’s degree and (d) have at least one student 
who will graduate with a Masters or PhD degree at the end of  the project. 
The application process for training fellowship is different from that of  the research grants. For training fellowships, applicants can only 
make applications to HRCSI after HRCSI has made request for submission of  applications. Calls for training fellowship applications are 
made twice in a year. Submission of  applications for research grants is open. There is no restriction on time when applicants can submit 
their research proposals to HRCSI.  That is, applicants can submit their applications throughout the year.   
The review of  research grant application proceeds in three stages. These are in-house screening, external and MRC review. In-house 
screening seeks to eliminate weaker proposals from the pool of  proposals. This allows subsequent reviews to focus on proposals are 
most likely to be funded. Proposals shortlisted in the in-house screening are sent to three external reviewers. External reviewers are 
independent experts who assess the scientific merit of  the proposal. The Multidisciplinary Research Committee (MRC) comprises 
independent scientists who adjudicate on views of  external reviewers. The MRC meets four times in a year to review research grant 
applications. The earlier in the quarter an application is submitted the higher the likelihood that it will be reviewed within that quarter. 
HRCSI communicates with applicants the outcome of  the results of  the review process within one month of  the MRC meeting. For 
more information and further details visit HRCSI website at: http://www.hrcsi.ncst.mw or email: hrcsi@ncst.mw. 
